Featured FARA News and Blogs
Reata Pharmaceuticals Announces
FDA Approval of SKYCLARYS™ (Omaveloxolone)
View the recently updated
Clinical Management Guidelines for Friedreich Ataxia
Available Now! FARA’s Annual Donor Impact Report
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
Clinical Trials now Enrolling Volunteers Needed!